DalCor Pharmaceuticals

Pioneering Pharmacogenetic Precision Medicine for Cardiovascular Disease

General Information
Company Name
DalCor Pharmaceuticals
Founded Year
2015
Location (Offices)
Montreal, Canada +1
Founders / Decision Makers
Peter Schuepbach - Vice President Technical Operations Michael Dixon - CFO Donald M. Black - CMO Louise Proulx - CDO Patrick Schneider - MD
Number of Employees
16
Industries
Health Care, Pharmaceutical
Funding Stage
Series D
Social Media

DalCor Pharmaceuticals - Company Profile

DalCor Pharmaceuticals is a Canadian-based startup focusing on pioneering pharmacogenetic precision medicine for cardiovascular disease. The company's flagship product, dalcetrapib, aims to reduce fatal and non-fatal myocardial infarction in a specific genetic subset of patients. Founded in 2015, the company operates in the Health Care and Pharmaceutical industries. In its most recent investment round, DalCor Pharmaceuticals secured a substantial $80.00M Series D investment on 13 September 2023. The investor group includes FSTQ, CTI Life Sciences Fund, Investissement Québec, Andes, T&B Pharma, and the Ministère de l’Economie, des Finances et du Budget. Overall, DalCor Pharmaceuticals' emphasis on precision medicine and its recent significant investment round showcase its potential for making a substantial impact in the cardiovascular disease treatment space.

Taxonomy: Precision Medicine, Cardiovascular Disease, Pharmacogenetic, Genetic Marker, Dalcetrapib, CETP Inhibitor, Pharmacogenomics, Clinical Insights, Myocardial Infarction, Acute Coronary Syndrome, Genetic Subset, Cardiovascular Events, Pharmaceuticals, Roche, ADCY9 Gene

Funding Rounds & Investors of DalCor Pharmaceuticals (4)

View All
Funding Stage Amount No. Investors Investors Date
Series D $80.00M 6
CTI Life Sciences Fund, investor in DalCor Pharmaceuticals 's Series D round Investissement Québec, investor in DalCor Pharmaceuticals 's Series D round Andes, investor in DalCor Pharmaceuticals 's Series D round
T&B Pharma, Fonds de solidarité FTQ +1 		13 Sep 2023
Venture Round $3.85M - 12 May 2020
Series B $100.00M 4
CTI Life Sciences Fund, investor in DalCor Pharmaceuticals 's Series B round Sanderling Ventures, investor in DalCor Pharmaceuticals 's Series B round
Caisse de Depot et Placement du Quebec, André Desmarais 		18 Apr 2016
Series A $50.00M - 12 Nov 2015

Latest News of DalCor Pharmaceuticals

View All

No recent news or press coverage available for DalCor Pharmaceuticals .

Similar Companies to DalCor Pharmaceuticals

View All
Verve Therapeutics - Similar company to DalCor Pharmaceuticals
Verve Therapeutics We are on a mission to protect the world from cardiovascular disease.
Dicerna Pharmaceuticals - Similar company to DalCor Pharmaceuticals
Dicerna Pharmaceuticals Pioneering breakthroughs in genetic disorders and liver diseases using RNA interference technology.
Cardio Diagnostics Holdings Inc. - Similar company to DalCor Pharmaceuticals
Cardio Diagnostics Holdings Inc. Making cardiovascular disease prevention and early detection more accessible, personalized, and precise.
ARCA biopharma - Similar company to DalCor Pharmaceuticals
ARCA biopharma Personalized therapies for cardiovascular disease through advanced genetic research
Renovacor - Similar company to DalCor Pharmaceuticals
Renovacor Advancing transformative therapies for cardiovascular disease
Circle Decoration Circle Decoration

Want to dive deeper into DalCor Pharmaceuticals ? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now